Modeling Stress-precipitated Smoking Behavior for Medication Development
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Smoking Cessation, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 9/12/2018 |
| Start Date: | October 2008 |
| End Date: | July 2019 |
The purpose of this study is to examine whether guanfacine or carvedilol will attenuate the
ability of stress to precipitate smoking lapse behavior in treatment seeking and
non-treatment seeking daily smokers. Participants seeking treatment for smoking will
participate in a smoking cessation attempt after the laboratory sessions. Also looking at
gender differences.
ability of stress to precipitate smoking lapse behavior in treatment seeking and
non-treatment seeking daily smokers. Participants seeking treatment for smoking will
participate in a smoking cessation attempt after the laboratory sessions. Also looking at
gender differences.
Inclusion Criteria:
- ages 18-60
- able to read and write in English
- smokers
Exclusion Criteria:
- any significant current medical conditions that would contraindicate smoking
- current Diagnostic and Statistical Manual IV (DSM-IV) abuse or dependence of other
substances, other than nicotine (or caffeine) dependence
- positive test result at intake appointments on urine drug screens conducted for
opiates, cocaine, or benzodiazepines
- women who are pregnant or nursing
- suicidal, homicidal or evidence of severe mental illness
- participants prescribed any psychotropic drug in the 30 days prior to study enrollment
- blood donation within the past 6 weeks
- participants who have engaged in a quit attempt in the past 3 months
- specific exclusions for administration of guanfacine/carvedilol not already specified
include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG; EKG
evidence at baseline screening of any clinically significant conduction abnormalities,
including a Bazett's corrected QT interval (QTc) >450 msec for men and QTc>470 msec
for women; known intolerance for guanfacine
We found this trial at
1
site
New Haven, Connecticut 06519
Principal Investigator: Sherry A McKee, PhD
Click here to add this to my saved trials
